DK1173549T3 - Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser - Google Patents

Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser

Info

Publication number
DK1173549T3
DK1173549T3 DK00941122T DK00941122T DK1173549T3 DK 1173549 T3 DK1173549 T3 DK 1173549T3 DK 00941122 T DK00941122 T DK 00941122T DK 00941122 T DK00941122 T DK 00941122T DK 1173549 T3 DK1173549 T3 DK 1173549T3
Authority
DK
Denmark
Prior art keywords
immune responses
mitogens
cytokines
pathological immune
inhibit pathological
Prior art date
Application number
DK00941122T
Other languages
Danish (da)
English (en)
Inventor
David A Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK1173549T3 publication Critical patent/DK1173549T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00941122T 1999-05-05 2000-05-05 Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser DK1173549T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13261699P 1999-05-05 1999-05-05
PCT/US2000/012284 WO2000066158A2 (en) 1999-05-05 2000-05-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number Publication Date
DK1173549T3 true DK1173549T3 (da) 2008-12-08

Family

ID=22454846

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941122T DK1173549T3 (da) 1999-05-05 2000-05-05 Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser

Country Status (9)

Country Link
EP (1) EP1173549B1 (de)
JP (2) JP4132013B2 (de)
AT (1) ATE404662T1 (de)
AU (1) AU771080B2 (de)
CA (1) CA2372956A1 (de)
DE (1) DE60039863D1 (de)
DK (1) DK1173549T3 (de)
ES (1) ES2311462T3 (de)
WO (1) WO2000066158A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
AU3066599A (en) 1998-03-03 1999-10-18 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
DE60042210D1 (de) * 1999-09-01 2009-06-25 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU5340001A (en) * 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
PT1471974E (pt) 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
TW201733599A (zh) * 2016-02-17 2017-10-01 醫療法人社團滉志會 以發炎性疾病為對象之醫藥
US12458249B2 (en) * 2018-03-29 2025-11-04 Demao Yang Cell therapy for patients
EP4422668A1 (de) * 2021-10-25 2024-09-04 Ellennbe GmbH Pharmazeutische zusammensetzung und kit mit einer immunmodulatorischen substanz zur behandlung von krankheiten
EP4169524A1 (de) * 2021-10-25 2023-04-26 Ellennbe GmbH Immunmodulatorische substanz zur verwendung in einem verfahren zur behandlung und/oder prävention einer krankheit
WO2024084038A1 (en) * 2022-10-20 2024-04-25 Ellennbe Gmbh Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747767B2 (en) * 1997-11-05 2002-05-23 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses

Also Published As

Publication number Publication date
WO2000066158A3 (en) 2001-02-15
AU5587300A (en) 2000-11-17
ATE404662T1 (de) 2008-08-15
EP1173549A2 (de) 2002-01-23
JP2008174564A (ja) 2008-07-31
AU771080B2 (en) 2004-03-11
EP1173549B1 (de) 2008-08-13
WO2000066158A2 (en) 2000-11-09
ES2311462T3 (es) 2009-02-16
JP4132013B2 (ja) 2008-08-13
DE60039863D1 (de) 2008-09-25
JP2002543152A (ja) 2002-12-17
CA2372956A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
DE69802191D1 (de) Festphase nukleinsäure-isolierung
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
DK1032705T3 (da) Probearrays og fremgangsmåder til at benytte probearrays til at skelne mellem DNA
NZ334691A (en) Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
DE69939864D1 (de) Ppar-gamma modulatoren
BR0112385A (pt) Meio de coleta universal
WO2005052139A3 (en) Method of inducing memory b cell development and terminal differentiation
ATE404662T1 (de) Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
NO20006600L (no) Ikke-peptidylinhibitorer av VLA-4-avhengig cellebinding nyttig for behandling av inflammatoriske, autoimmune og respiratoriske sykdommer
EP1102988B8 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
ATE331791T1 (de) Phosphodiesterase 10
DK0866968T3 (da) Fremgangsmåde til in vitro analyse af toksiske og allergene stoffer
DK1028738T3 (da) Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser
NO961031D0 (no) Fremgangsmåte til å drepe uönskede målceller
EP1601687A4 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
FR2781674B1 (fr) Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
NO20012100L (no) Pyrano-, piperidino- og tiopyranoforbindelser og fremgangsmåter ved anvendelse
WO2002077178A3 (en) Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
MXPA03011009A (es) Metodos para mejorar la actividad de lineas celulares en dispositivos de inmunoaislamiento.